Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB/Flu-05E Intranasal Vaccine for Tuberculosis Prevention
NCT06873282Phase 2Completed
- Sponsor
- Smorodintsev Research Institute of Influenza
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing TB/Flu-05E with Placebo (2 arms). Primary endpoints: Level of TB antigen-specific cytokine producing T-cells at Day 21 and Level of TB antigen-specific cytokine release in whole blood assay at Day 21. Started Dec 2023; status: completed.
02
Drugs
TB/Flu-05E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06873282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873282.